Literature DB >> 2379773

Development of motilin receptors and of motilin- and erythromycin-induced contractility in rabbits.

I Depoortere1, T L Peeters, G Vantrappen.   

Abstract

The development of the motilin receptor was studied through contraction and binding studies of groups of three rabbits aged between 2 and 289 days. The contractility of small intestinal smooth muscle strips was measured isotonically. The aborally decreasing gradient in response to motilin, known to exist in adult rabbits, was already present at day 8 (maximum contractile responses expressed as a percent of the maximal response to acetylcholine were 77% +/- 9%, 34% +/- 10%, and 25% +/- 8% for duodenal, jejunal, and ileal strips, respectively). Throughout the observation period, the doses of motilin and its agonist erythromycin that were required to induce 50% of the response remained constant and were not significantly different from doses required for adults (their negative logarithms were 8.55 +/- 0.35 and 5.70 +/- 0.25, respectively). The correlation between the maximum contractile response toward motilin and erythromycin was almost perfect (r2 = 0.82). Binding studies with iodinated norleucine13-porcine motilin were performed using antral smooth muscle tissue homogenates. The maximum number of binding sites increased rapidly after 8 days (3.3 +/- 0.4 fmol/mg protein) and reached a peak at 21 days (20.7 +/- 1.4 fmol/mg protein), but decreased at that point toward the adult value (40 days, 10.6 +/- 1.3; 289 days, 9.8 +/- 1.1 fmol/mg protein). The dissociation constant, however, remained unchanged. The peak value of receptor density occurred at about the time that the rate of increase of the length of the intestine and of the weight of the antrum were at maximum levels (at 18 and 27 days, respectively). Motilin receptors are expressed early postnatally, and the regional gradient in sensitivity towards motilin is also established soon after birth. If applicable to humans, an early response to erythromycin may have therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379773     DOI: 10.1016/0016-5085(90)90951-v

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  R C Horton; M J Kendall
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

Review 2.  In Search of the Ideal Promotility Agent: Optimal Use of Currently Available Promotility Agents for Nutrition Therapy of the Critically Ill Patient.

Authors:  Sarah J Diamond; Endashaw Omer; Laszlo Kiraly
Journal:  Curr Gastroenterol Rep       Date:  2017-11-16

Review 3.  Erythromycin and the gut.

Authors:  S M Catnach; P D Fairclough
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

4.  Motilin and erythromycin enhance the in vitro contractile activity of the sphincter of Oddi of the Australian brush-tailed possum.

Authors:  R A Baker; G T Saccone; D Costi; A Thune; J Toouli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

5.  Interactions of pre-operative erythromycin administration with general anaesthesia.

Authors:  P Narchi; D Benhamou; M Elhaddoury; C Locatelli; H Fernandez
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.